One Nucleus Q4 Annual Update by One Nucleus

Annual Review 2021 Q4

Media Partner

Where Life Meets Science Chesterford Research Park offers state of the art laboratory and office space alongside superb central facilities - a community perfectly positioned for today’s thriving pharmaceutical, biotech and technology companies.

www.chesterfordresearchpark.com

savills.co.uk

01223 347 000

Contents Welcome ......................................................................................................... 4-6 Meet the Team ................................................................................................ 12 Our Corporate Supporters ..........................................................................13 Our Corporate Patron .................................................................................. 14 One Nucleus Partners .................................................................................. 15 Partner Programme ...................................................................................... 16 Member Benefits ..................................................................................... 18-19 Member Savings ...................................................................................... 20-22 Facilities Management ................................................................................ 23 A Year in the Life of a Pandemic......................................................... 31 -33 It Takes a Network ................................................................................. 48 - 50

Member Listings: A-Z Listing ................................................................................................. 53-60 Find Out More ................................................................................................ 61

www.onenucleus.com | 3

A Warm Welcome from Tony Jones This yearly publication provides the opportunity for us to reflect on a year of One Nucleus activities, to highlight some of the successes and insights gained by our members and wider Life Sciences sector as they progress their businesses and take a look forward in terms of plans for the year ahead. In addition, it enables us to set out the characteristics of our network, the engagement opportunities available and some of the One Nucleus thinking around how we support our members going forward. And what a year it has been between March 2020 and writing this article. Greater details of some of the trends, deal highlights and thought leadership in key areas are set out in the articles that follow. In this section I would just like to offer you a warm welcome to the One Nucleus Annual Review and set the scene for the subsequent content. Progress in unprecedented times It would be impossible to reflect on the past year without considering the context of Covid-19, how the sector has been successful in responding to create diagnostics, vaccines, treatments to combat Covid-19 as well as generating an immense amount of scientific understanding of the SARS-CoV-2 virus. There is still a long way to go to fully understand the virus and indeed how to live with it, but it has undoubtedly been a year of unprecedented progress and collaboration at scale. From the strong academic base through to large multinational pharma; including the innovative SMEs; their professional advisers and investors, it is hard to see any segment of the One Nucleus membership that has not been actively involved in helping the world deal with the pandemic. It should not be forgotten that progress was not only against Covid-19. There have been many significant product development, investment and technological advance highlights in other therapeutic areas throughout the year. This breadth of success illustrating the resilience and adaptability of the Life Science institutes and companies to remain so active. Sector Highlights Globally, it has been reported that biotech raised $42 billion in 2020 across 1851 deals (A Khemlani), a massive 46% increase over 2019 in terms of money raised yet only a 4% increase in deal numbers. Closer to home, the UK Life Science sector also had a record year, raising £2.4Bn. The current year is on course to be an even greater value if the deal activity remains high. Clarivate/BIA notably reporting last month that £830 million having been raised in the three months to the end of February 2021 – almost as much as the first six months of 2020. Mergers and acquisitions have been stellar also. Business Weekly reporting that M&A deals in the previous year for the Cambridge region alone had topped £100 billion. The increased popularity of SPACs (special purpose acquisition vehicles) is seeing traditionally earlier stage investors be more involved companies going to IPO. Is this growth in interest driven by the spotlight now placed on the value the sector can bring to society and will investment levels scale down when interest rates start to rise, perhaps 2021 will begin to provide some answers.

4 | One Nucleus Annual Review & Directory 2021/2022

The year at One Nucleus As for all organisations, the disruption of the pandemic and the required adaptation to activities provided One Nucleus with challenges yes but also a chance to reflect on our strategy, consider how our members needs have evolved and evaluate where we focus resources into 2021 and beyond. The loss of face-to-face events changed to some degree how we delivered our events, profiled our members and region and channelled information to members. Changing Government guidance, new funding opportunities and indeed enabling peer-to-peer knowledge sharing were well received and leveraging our new-found confidence in online event delivery meant we engaged our international collaborators with our network much more actively. Key delivery highlights include: • Three conferences delivered - ON Helix, Genesis and Building Life Science Adventures. Collectively the events attracted over 1,000 registrants, 100 speakers and an impressive legacy of recorded sessions for continued on-demand learning. • Over 50 online events across topics in R&D innovation, funding, HR, marketing, collaboration and more. • Delivery of online Training Courses, ensuring businesses were able to continue developing their teams through the pandemic. • Launch of our Virtual Innovation Centre. An initiative that was in the pipeline for One Nucleus long before we had to be more virtual due to Covid-19. • The Group Purchasing Scheme has saved our Gold members in excess of £3M in the past year and has also provide direct links to key suppliers such as Thermo Fisher who have worked with us to guide members through the pandemic and Brexit in terms of securing lab supplies. • Collaboration with our members has gone from strength to strength. The continued support and input from our sponsors and members has meant we have been able to create event content targeted at their information and engagement needs. On the flip side, our ability to offer members a 3-month extension to their membership year on renewal has been well received as our way to offer support in challenging times. • Relocation of the One Nucleus office to Babraham in May 2020 now seems a long time ago, but we look forward to maximising our presence there when restrictions are removed. Looking Ahead with One Nucleus As alluded to above, the year has provided space to develop our forward strategy, taking on board the guidance from members as we all move to the post-Covid brave new world. It is important to One Nucleus that we always align our approach as closely as possible to our mission and principles. It is all too easy for not-for-profit membership groups such as One Nucleus to suffer mission drift when they have been evolving over decades. Our mission remains the same, to support our members in being globally competitive, seeing great science and innovation translated into improved patient outcomes and value creation for all stakeholders. One Nucleus is fortunate to work with such an innovative ecosystem of members and collaborators that truly changes lives for the better. All parts of the ecosystem need to function and be innovative in what they do for the maximum collective impact.

www.onenucleus.com | 5

That includes One Nucleus if we are to play our part fully. Supporting our members; facilitating knowledge exchange, connections and deal flow; and helping attract investment and talent to our cluster whilst minimising the overhead placed on our sector as they support us. This latter point is where we strive to be innovative, collaborative and adaptable. Looking forward, there are four key quadrants of One Nucleus activity and focus which are illustrated in overview here with further details later in the document and on the One Nucleus website.

Innovation Support • • • • • • • •

Promotion of Government support mechanisms Connecting to the private investor base Operational support and access to expert advice Profile raising Networking, partnering and business development Facilities Management and Purchasing support Special Interest Groups Virtual Innovation Centre programme

People • • • • • • • • • •

Events • • • • • • •

Conference Portfolio - (ON Helix, Genesis, Building Life Science Adventures) Innovation Seminars Roundtables Partnering Days Collaborations BioWednesdays Networking Mixers

Learning & Development course portfolio Recruitment support Careers events Online job listings ‘Employer of Choice’ sessions People Pathways newsletter On-demand learning centre Skills Advisory Group HR Special Interest Group Patient/Research Charities Engagement Plan

Regional Champion • • • • • • •

Company stats/R&D pipeline/investment Promotion to inward investors and partners Publication of commentaries & reports Global exhibition/conference attendance Stakeholder Engagement/Advocacy Attracting Partnering Days Building through collaborations

Any Questions Provoking good questions; connecting the best innovation; and working with the best partners is key to seeing patients benefit from scientific and technological advances. One Nucleus is fortunate and privileged to sit at the heart of such a world leading membership and network that strives every day to translate advances in biomedicine and healthcare into better healthcare interventions. I hope you enjoy reading our Annual Review, gaining the knowledge that helps you to identify the best route forward and the most suitable companions to take it with. Success is a team effort and the One Nucleus team very much looks forward to assisting you on your journey. Best wishes, Tony Jones, CEO

6 | One Nucleus Annual Review & Directory 2021/2022

Innovation Support Supporting innovation is the raison d’être of a group such as One Nucleus. Irrespective of the stage of a company’s or project’s development, innovation sits at the heart of how to take that new product from bench to bedside. Innovation is not just about science and technology, creativity is equally valuable when arising in areas such as deal making, regulatory pathways and leadership styles such that the true benefit of great ideas is maximised for all stakeholders. Working with our members and collaborators to share knowledge, raise opportunity awareness and facilitate the right connections, supporting innovation is the common thread that runs comprehensively through all One Nucleus activities. Some of the key activities we undertake include: Funding: Accessing capital is of course critical to developing new products. As a membership-based organisation, One Nucleus does not provide investment capital or grants directly to life science businesses, but we do build connections and awareness of routes to capital and share this with our members. On-going tracking of available public sector schemes enables us to share that information with our members via our eNews, website and social media accounts. We nurture connections between private capital sources and our members, creating two-way awareness of opportunities. A recent development in 2020 has been venture funds, such as Advent Life Sciences and Cambridge Innovation Capital joining the One Nucleus Partner Programme to not only move themselves closer but also their respective portfolios to enhance both ecosystems. Operational Support: Leveraging the One Nucleus ecosystem to connect to expert advisers, special interest groups and practical facilities and purchasing support for those key roles within companies, means our members can focus on growth and the competitive edge of their approach. Business Development: Platforms to raise our members’ profile in the minds of partners, investors, customers and potential employees include our events, conferences, Annual Review, website and social media channels. Virtual Innovation Centre Launched in January 2021 this new initiative from One Nucleus is targeted at growth stage life science companies, many of whom will have benefited from the numerous start-up focussed accelerator and innovation centre models. Looking to their next stages, this precision support approach harnesses the global strength of our ecosystem and network, supporting leaders as they seek investment, partners and greater operational demands as illustrated below. • • • • • •

12-month tailored seminar programme. 1-2-1 meetings with leading experts. Profile at One Nucleus and external conferences. Directed 1-2-1 introductions. International connectivity. Gold membership benefits.

For more information, please contact Aline Charpentier, Head of Innovation Support at One Nucleus www.onenucleus.com | 7

People Focus and news flow is often on highlighting world leading technology breakthroughs and impressive investment rounds and deals in the Life Sciences sector as life-changing products are invented and translated to improved patient care. It is vital not to forget the third pillar that supports the enviable track record, that inventions, collaborations deals and therefore impact requires people. One Nucleus supports members, individuals and the wider sector through a suite of interventions targeted to meet the aspirations of our members which can be summarised as follows: Attract the best talent and skills. Engender loyalty. Harness the strengths of diversity Encourage innovation at all levels Be a good corporate citizen delivering value for all stakeholders.

Motivate their employees. Operate an open and safe environment. Enable personal development of their staff. Deliver fair reward for performance. Offer flexibility to meet business and employee needs in an equitable manner.

Learning & Development: Business leaders frequently confirm that their company’s employees are its most valuable assets. A mantra that has never been more relevant than now when competition for the best people has never been more intense. Retention and development of staff is as key to successful growth as effective recruitment. We have developed a range of Learning and Development support opportunities including: •

A broad Training Course portfolio, delivered face-to-face or online to meet member companies’ needs.

• Training Courses can be delivered in-house for a single company or open courses as required. •

Members receive up to 30% discount on Training Courses when booking.

• Free on-demand content from our events and conferences to fill knowledge gaps within teams. Recruitment & Retention: • Website listing of job vacancies. •

Focussed ‘Employer of Choice’ sessions to discuss best practice.

•

Thematic forums in Skills and HR.

• Annual Building Life Science Adventures conference People Pathways Newsletter: •

Monthly e-publication disseminated to our network.

•

Learning & Development insight articles.

•

Recent appointments at member companies.

•

Current vacancies.

•

Up-coming Training Courses.

For more information, please email our One Nucleus Learning and Development team 8 | One Nucleus Annual Review & Directory 2021/2022

Events Connecting and meeting with peers is a vital part of business practice and our range of forums is designed to meet the needs of our network in terms of content, format, timing and modes of delivery. Our conferences and events provide the ideal platform for business-to-business interactions. The Covid-19 disruption forced us all to experience the shift to virtual events. Such enforced learning however does provide the opportunity to consider the benefits of new modes as well as what is missed. We aim to combine the best of both these meeting place worlds. Our events portfolio has both face-to-face and online events, in a balanced approach to share key information, debate emerging trends, generate new relationships and maximise accessibility to our community irrespective of geography. Future events will include: BioWednesdays: Monthly opportunities for a broad range of members and non-members to come together for peer-to-peer debate around current trends, challenges and opportunities within the sector. 2020 demonstrated these events worked extremely well online with high participation and discussion. They will remain that way, addressing the lost in-person networking by the means below. Networking Mixers: Our ‘Pub Socials’ started in April 2011 and have demonstrated a successful track record over the intervening decade. Bringing our network together in an informal manner to nurture relationships with contacts old and new. Networking is a powerful tool in business and many great deals, careers and ideas are forged in the bar! (Or over coffee, lunch or afternoon tea of course). Innovation Seminars: Built in partnership with our Partners and Sponsors, each event being a high content mix of presentations and/or debate around key technical or business challenges in the sector. These sessions, often free to attend and by invitation only, range from closed roundtable meetings to full-day seminars depending on the innovation journey under discussion. Partnering Days: Tailored in response to an innovation-seeking BioPharma corporate, these sessions create the platform by which their business development and technology scouting teams can engage with our network of early-stage R&D companies and institutions. Each one bespoke, they can contain one or more of corporate presentation and wish list, external expert speakers to stimulate engagement, 1-2-1 partnering and targeted follow-up mechanisms. Collaborative Events: Facilitating the convergence of our network with complementary networks from related technology fields or different geographies is an effective means to help our members build those all-important new relationships. One Nucleus maintains strong collaborative relationships with a multitude of such groups, both across the UK and internationally for just this sort of member-to-member connectivity with organisations like us. Conferences: The focal points of the One Nucleus events calendar, summarised overleaf. With free digital attendance for each One Nucleus member company, these larger gatherings provide the ideal opportunity to connect at scale. Our main events are: ON Helix - focussing on translational research and the ecosystems that enable it. Genesis – our largest annual event focussing on investment, technology development and deal trends in the sector. Building Life Science Adventures – debating how great careers are created and nurtured in great companies. For more information, please contact Alicia Gailliez, Business Development Manager www.onenucleus.com | 9

Our flagship conference, ON Helix, brings our network together to present and discuss the main innovation and technology trends in healthcare research and development. Following 2020 and the way the life science community combined resources, ingenuity and hard work to deliver prophylactic and therapeutic tools against the pandemic, many lessons can be learnt on better translating science and developing therapeutics and healthcare technologies. Throughout the one and a half days of ON Helix, speakers will address the latest innovations and technologies in Medicines Discovery in a Brave New World.

Building on the evolution of the past 20 years, Genesis 2021 will assemble senior executives and decisionmakers from across the Life Science, Healthcare and Technology field to present, discuss and demonstrate their collective insight and thought leadership for the sector, themselves and their stakeholders. • • • • •

High content mix of plenary talks and panels from key opinion leaders An Innovation Workshop area for further technical and business insights Face to face networking and digital 1-2-1 meetings with delegates from across the international Life Science and Healthcare industry The Genesis Fringe Events Series All One Nucleus member companies to receive one digital free pass

Creating careers not just jobs is a two-way process between those seeking to build their adventures in science and those seeking to employ them with academia a critical enabler. This two-day free to attend digital careers conference is a chance to fill knowledge gaps, debate best practice and connect to enable success. Not your standard job fair, this is an event bringing panels of students, early career seekers, employers and universities together to engage in lively discussions over the course of two days.

10 | One Nucleus Annual Review & Directory 2021/2022

european biologics capabilities. better treatments. locally supplied. Clinical | Commercial | Life-cycle Management

coming soon! new clinical center of excellence

brussels, belgium

limoges, france

anagni, italy

Catalent Biologics is your premier European provider for integrated development, manufacturing and packaging of biologics and sterile injectables. Combined with newly available high-speed vial and syringe filling lines, our proven tech transfer expertise can help deliver your late-stage and commercial drug products to patients, faster. Vials | Pre-Filled Syringes | Cartridges | Auto-Injectors | Safety Devices

www.onenucleus.com | 11

Meet the Team

Tony Jones

Chief Executive Officer

Debbie Flicos

Finance & Systems Administrator

Alicia Gailliez

Business Development Manager

Richard Dickinson

Chief Technical Specialist

Laura Bacchus Finance and Data Administrator

Claire Abrams

Director of Events & Communications

Natalie Keuroghlian Marketing Manager (maternity cover)

12 | One Nucleus Annual Review & Directory 2021/2022

Jean

Chief Operating Officer

Aline Charpentier

Head of Innovation Support

Jasmin Bannister

Events & Communications Administrator

Corporate Patron

Corporate Sponsors

www.onenucleus.com | 13

Our Corporate Patron

One Nucleus is delighted that AstraZeneca will continue its long-held relationship as Corporate Patron. Over the decade of support to date, AstraZeneca has provided a number of its staff as advisors, speakers and steering group members to help deliver strategic guidance to One Nucleus as one of the region’s key stakeholders. Highlighting AstraZeneca’s commitment to the partnership with One Nucleus, it is our pleasure to have Penny James, Chief Operating Officer BioPharmaceutical R&D as a Non-Executive Director. The breadth of this engagement means we have formed a strong and productive relationship with AstraZeneca, based on shared ambitions for the Cambridge and wider UK life sciences community. The shared ambitions for the region’s life science cluster to be the world-leading bioinnovation hub is key to both of our organisations. One Nucleus strives to enable knowledge sharing on the latest innovations in the scientific, business and investment aspects of the sector. AstraZeneca’s willingness to dedicate strategic resource to us, such as event speakers and updates, significantly enhances our delivery. Their engagement provides insight to the nascent companies, their founding entrepreneurs and investors, on how exceptional scientific innovation can be translated into patient benefit globally. This fits well with the collective aspirations of our cluster’s ecosystem; to create life changing technologies and products that have a global impact on lives. AstraZeneca’s role as a global leader and regional champion, in terms of science and societal impact has never been more evident as in their response to the COVID-19 pandemic. Leading the charge in development and supply of vaccines; their non-profit supply pledge to enable global access; local engagement in mentoring-style schemes; and strong practices on environment and diversity exemplify the aspirations of the cluster and One Nucleus’s desire to promote best practice. Tony Jones, CEO

14 | One Nucleus Annual Review & Directory 2021/2022

One Nucleus Partners Babraham Research Campus

www.onenucleus.com | 15

Partner Programme The One Nucleus Partner Programme offers a fully integrated value proposition to organisations seeking to play an influential and visible role in the development of the One Nucleus life science community.

Relationship Management: Each Partner has a tailored Annual Engagement Plan, developed to ensure a good strategic fit with the Partner’s goals for the year ahead and against which performance can be managed. There is an allocated One Nucleus account manager for each relationship to ensure regular reviews and discuss desired adjustments as the year progresses. Engagement may include benefits from the menu below, but the agreed package is designed with flexibility in mind. Partner Benefits: • One Nucleus Gold Membership. • Company logo displayed with advised url hyperlink on the One Nucleus website. • Company logo and url hyperlink in the One Nucleus Annual Review. • Opportunity to speak at One Nucleus events (based on relevance and experience). • Contribution of thought leadership articles to One Nucleus publications. • Placement of a banner advertisement and article in an edition of One Nucleus eNews. • Option to develop bespoke event(s) or workshop(s) to be delivered with One Nucleus. • Three digital delegate passes to any One Nucleus conference offering such an option. • One in-person delegate pass to any One Nucleus conference offering such an option. • Annual 1-2-1 meeting with the CEO of One Nucleus to discuss issues facing the life science sector and possible One Nucleus interventions. • Priority invitation to any VIP-only events hosted by One Nucleus. * To become a One Nucleus Partner the cost is £7,845 +VAT per annum

For information:

+44(0)1223 896450

info@onenucleus.com

16 | One Nucleus Annual Review & Directory 2020/2021

www.onenucleus.com

Enabling a healthier world

Guaranteed* 12 Months from Gene to IND Explore Ibex® Design Ibex® Design is our fastest gene-to-IND offering, delivering GMP drug product for your clinical phase 1 trials within 12 months, with an option to supply tox drug product in only 9 months. We are the only CDMO offering a comprehensive gene to IND program with submissionready CMC data for your IND/IMPD in 12 months with guaranteed* deliverables.

* For antibodies and antibody like molecules. From receipt of the gene sequence. Subject to terms and conditions.

Did You Know? Connect via groups in the EU, North America, Asia & Australasia and Asia

Post job vacancies online

Access the on-demand library of debates and information

Save more than your membership fee via member discounts

As a member you can...

Access the Learning & Development centre for your team

Network with investors, collaborators and customers

Do get in touch to learn more about membership benefits and how to maximise the return on your investment 18 | One Nucleus Annual Review & Directory 2021/2022

Be seen as an employer of choice

Raise your company’s profile

Benefit

Gold

Silver

Non-member

Listed in online membership directory

Yes

Listed in One Nucleus Annual Review

Yes

Post news to website and social media

Yes

£75 + VAT*

Advertise jobs on web site

Free

£75 + VAT*

Advertise events on web site

Free

£75 + VAT*

ON Helix Digital Delegate 2021

1 Comp Pass/member Extras £90 + VAT

1 Comp Pass/member Extras £120 + VAT

£150 + VAT

Genesis Digital Delegate 2021

1 Comp Pass/member Extras £90 + VAT

1 Comp Pass/member Extras £120 + VAT

£150 + VAT

Genesis In-person Delegate 2021

£295 + VAT

£395 + VAT

£495 + VAT

BioWednesdays

Free

£50 + VAT

A4 Advert in eNews

£500 + VAT

£800 + VAT

Innovation Seminars

Free

Invitation Only

Training

30% discount

15% discount

List Price

Facilities Management Consultancy Day Rate

£610 plus expenses + VAT

£700 plus expenses + VAT

£875 plus expenses + VAT

Preferred Supplier Discounts

Yes

Yes**

Access M2M Marketplace discounts

Yes

Access to Themed Interest Groups

Yes

Yes**

Employer of Choice Sessions

Free

Invitation Only

Access to on-demand library

Yes

Restricted

*coming soon **Access to some but not all

www.onenucleus.com | 19

Member Savings Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. One Nucleus negotiates savings and discounts for members by leveraging the critical mass of our membership, providing members with the purchasing power of a large entity. Receive discounted rates on laboratory supplies, services, key industry events and more.

Group Purchasing Scheme: • Seven competitively won Preferred Supplier contracts. • Saving members over £3 million per annum on a combined spend of £7 million per annum. • Member retains full control over their own procurement, which is key to R&D operations. • Member has direct relationships with the suppliers, including access to services which are customised to their needs. • Gold Members using Fisher Scientific receive a growth rebate on their annual spending at the end of the year. The overall savings made easily cover the cost of a Gold Membership. • All Preferred Suppliers have published sustainability plans and policies to protect customers’ environmental footprint. • Contact Richard Dickinson for more details including a cost/benefit analysis.

Retain Control We fully understand that Life Science procurement is not a ‘one size fits all’ approach – with One Nucleus’ savings options, you keep control of your own procurement, supplier relationships and get the best possible price.

Member to Member Marketplace: • •

Convenient destination to find an array of discounted products and services. Over 20 Support Suppliers offering discounts to One Nucleus members.

20 | One Nucleus Annual Review & Directory 2021/2022

Events: • • •

A free Digital Delegate Pass worth for each One Nucleus member company to ON Helix and Genesis. A combined saving of £300 + VAT over non-members. Discounted delegate rates at ON Helix and Genesis for in-person or additional digital delegates. A range of discounts at international and national industry partnering events and conferences such as BIO-Europe Spring, BioTrinity, BioNJ Annual Partnering Conference, AngloNordic Conference, Bio-Integrates, BIO Convention, Medi-Integrates, NLSDays and Bio-Europe.

Facilities Management: • Accessing expertise - Our Chief Technical Specialist, Richard Dickinson, has over 25 years’ experience as a Facilities Manager. • Provision of project management for office and laboratory fit-outs and can assist with laboratory service contracts, maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting. • Daily Rates (excluding VAT) – Gold members £610 plus expenses; Silver £700 plus expenses; Non-member £875 plus expenses. • View case studies. • Contact Richard Dickinson to discuss your needs and secure a quote.

www.onenucleus.com | 21

Member Savings in 2020 The chart below is a snapshot of our members, ranging from extra large to micro and demonstrates the savings made by them using the Purchasing Scheme. For some, the rebate alone covered the cost of membership.

Full price Purchasing scheme price Rebate Cost of membership

Extra Large

£654,630 £396,392

39% saving

£9,277 £7,380

Large

£331,881 £202,337

39% saving

£4,497 £4,965

Medium

£336,395 £177,475

47% saving

£1,159 £3,190

Small

£51,605 £31,773

38% saving

£653 £1,200

Micro

£189,194 £115,759 £2,819

39% saving

£720

22 | One Nucleus Annual Review & Directory 2021/2022

Facilities Management Facilities management can be a real problem for small technology companies with challenging demands for laboratory, workshop and office space. One Nucleus provides a range of Facilities Management Services to help our member companies to expand or relocate. We can provide project management for office and laboratory fit-outs (no job too small) and can help with laboratory service contracts, maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting. As with all our services, these are provided at discounted rates to our members. Our Facilities Management Services and Purchasing Scheme are managed by Richard Dickinson, One Nucleus’ Chief Technical Specialist, who has more than 25 years’ experience in laboratory and facilities management. Richard has extensive local contacts and is also NEBOSH certified in health and safety. Recent projects and clients include: • Alloy Therapeutics (UK) Ltd • Aqdot Ltd • Artios Pharma Ltd • Enplas Europe Ltd • Metrion Biosciences Ltd • Axol Bioscience Ltd • Microbiotica Ltd • Mestag Therapeutics Ltd • PhoreMost Ltd

www.onenucleus.com | 23

Success is our science The life sciences sector is hugely innovative but also highly complex and regulated. Our renowned multi-disciplinary team of lawyers have deep sector knowledge and can help wherever you need, whether that is to protect your latest idea, to execute complex transactions or deal with compliance issues. We provide the solutions to enable you to seize the opportunities open to you.

To find out more, please contact: James Fry Partner and Head of Life sciences james.fry@mills-reeve.com

www.mills-reeve.com

24 | One Nucleus Annual Review & Directory 2021/2022

Transformative transactions Businesses across the UK have dealt with significant upheaval over the past year, with the arrival of 2021 coinciding with the end of the post-Brexit transition period just as the country entered into its third national lockdown. Despite these challenges, British biotechs have continued to make significant advances across the diagnostic, biologic and drug discovery sectors. The successful development of the COVD-19 vaccines and subsequent rollout demonstrates this in ways we didn’t think were possible 12 months ago. UK-based biotech companies raised a total of £2.8 billion in 2020, marking the best ever year for the sector, including a record £1.39bn invested into private UK biotechs and £515m raised in follow-on financings by AIM listed biotechs alone (the most since 2015). The heightened focus on the life-sciences sector and unprecedented financial investment has not, however, resulted in a flurry of traditional IPO activity and despite a noticeable increase in early stage IPO enquiries, there were only four UK biotech IPOs in 2020 (two on NASDAQ and two on AIM). We are increasingly being asked to advise companies on alternative routes to market. 4Basebio UK Societas had its successful admission to AIM and move to Cambridge, UK in February. This was one of the final cross-border EU transfers to take place and involved the transfer of the company’s corporate seat from Germany and conversion of the company into a ‘United Kingdom Societas’ following the UK’s renegotiation of its relationship with the European Union. UK biotechs are also using M&A structures to obtain public listings on NASDAQ and AIM. In November 2020, we advised Cambridge company, F-Star Therapeutics on the UK aspects of its reverse-merger into NASDAQ-listed Spring Bank Pharmaceuticals to give the venture backed UK biotech a public listing without undertaking a traditional IPO. We are also being asked to advise UK private companies on potential SPAC (special purpose acquisition vehicle) related transactions, both in the context of companies who are considering a SPAC merger to gain access to significant capital and the public markets and for companies that have assets that are the target of SPACs. SPAC IPOs in the US have increased dramatically (59 in 2019 compared to 248 in 2020). For more information, or to discuss your business plans and options, contact Kristian Shearsby, 0207 648 5255 / kristian.shearsby@mills-reeve.com

Source: Market figures are reproduced from the BIA publication: “The science of success: UK biotech financing in 2020. February 2021

www.onenucleus.com | 25

Source: Market figures are reproduced from the BIA publication: “The science of success: UK biotech financing in 2020. February 2021

26 | One Nucleus Annual Review & Directory 2021/2022

Exits vs Unicorns and the future of British biotech The high-profile Cambridge biotech acquisitions of early 2021 have left some in the industry mulling over the apparent contradiction of exits from the UK by promising talents and the government’s desire for science “unicorns”. Starting off the new year, French biopharma Sanofi bought monoclonal antibody maker Kymab in January for USD 1.45 billion. A few weeks later, Ireland’s Jazz Pharmaceuticals took out GW Pharma, the cannabinoid drug maker, for USD 7.2 billion. Did these exits represent a failing of the UK’s investment structure, or on the contrary did it send positive signals about the vigour of the UK science sector and the rewards to be had for investing? Barbara Domayne-Hayman, entrepreneur-in-residence at The Francis Crick Institute sees both sides. The good side to an exit, she says, is that founders gain confidence to go on to create the next venture, often willing to take more risk the second time around. From the investor side, Will Walker-Arnott, senior investment manager at Charles Stanley Wealth Management, takes the view that everyone gets a boost out of a takeover: “It inflates valuation to the sector and everyone benefits”. Also optimistic is Eddy Littler, CEO of antiviral therapy developer ReViral, pointing out that if a biotech finds success midstage, and is bought out for a good premium, investors get their money back and have an incentive to reinvest. Just as importantly, “the people working in the biotech sector are recycled,” he says, “especially in Cambridge. They become serial entrepreneurs.” There are obvious examples such as Sir Greg Winter, but there are many others, including Tom Weaver, CEO of PetMedix, which he likens to “Kymab for dogs”. It is one of five start-ups he has co-founded, two of which were sold. However, as Barbara Domayne-Hayman notes, there is a downside to a sustained pattern of high-level exits. She recalls that Kymab had been touted as one of the few that would stay the course and become the UK version of Amgen, the US biotech pioneer with annual revenue in excess of USD 25 billion. Setting this in context, Professor Sir John Bell’s 2017 report for the government on Life Sciences Industrial Strategy called for the creation of several life science “unicorns” (companies valued at over USD 1 billion). His report came just a few months after the Nasdaq listing of Nightstar Therapeutics, the gene therapy spinout from Oxford University, leading to press speculation that UK policymakers were concerned about a rising British biotech star listing across the pond. Two years later Nightstar was acquired by American multinational Biogen, highlighting the hurdle the government faced if it was serious about nurturing life science unicorns. One of the team behind Professor Bell’s report was Eliot Forster, CEO of F-Star Therapeutics, the Cambridge-grown biopharmaceutical with a clinical pipeline of tetravalent mAb2 bispecifics. While acknowledging the economic contribution UK unicorns would make to long-term industry growth, he has experienced the challenges of achieving that kind of valuation. After successfully partnering for several years, F-Star pivoted to a wholly owned program strategy in 2018, for which it needed financing. “We explored several routes but the one that came most quickly was Nasdaq listing through an RTO (Reverse Takeover) with Springbank Pharma. Only Nasdaq had the depth of capital we needed to raise finance for our clinical programs.”

www.onenucleus.com | 27

According to figures from Trading and Investment News, since 2015 nearly 40% of UK biotechs seeking to go public have chosen Nasdaq, accounting for over 70% of total funds raised through UK biotech IPOs. In contrast, the 60% of biotech companies that have listed on London’s AIM exchange have raised just 20% of the total. And of the four most recent UK biotech IPOs, three have had £100 million-plus Nasdaq launches—Freeline Therapeutics, Compass Pathways, and Immunocore—with only Verici DX listing on AIM at a valuation of £14.5 million. London listing is still viable though, especially for companies that have revenue: Abcam launched on AIM in 2005 and CEO Alan Hirzel maintains it is a good platform from which to grow. DNA sequencing device maker Oxford Nanopore is also eyeing a London IPO, with an initial stock market valuation of £2.3 billion. Commentators have viewed this as a major boost in the UK’s quest to become what Boris Johnson envisages as a “Science and Tech Superpower”. Unlike most biotherapeutic companies, however, Nanopore has revenue, making it more attractive to FTSE investors. So what does it take to develop an investment ecosystem that encourages biotech companies to stay in the UK? One approach taken by government is to exert tighter control over acquisition of strategic tech assets through the National Securities and Investment Bill, which comes into law later this year. The more obvious answer to stemming exits is to make more capital available, especially the series C/D investment seen as requisite to allowing companies to scale up and bridge the gap to the equities market. Rishi Sunak’s announcement in the March budget that pension funds would be made available for investment in technology has raised hopes of replicating the venture capital climate of the US, kickstarted in 1979 when the US government eased pension investing through the Employee Retirement Income Security Act (ERISA). But the solution is not simply to make more money available, counters Daniel Mahony of specialist fund manager Polar Capital. “It’s simplistic to say that we are selling all our best companies and we need a big pot of gold to keep them going,” he says. “The fundamental problem in the UK is that we don’t have an end market. If you’re developing a drug that’s a cell therapy for oncology, the market is in the US and you’re going to have to go there at some point.” Perhaps the most realistic approach to the exits vs unicorns discussion is recognising that almost all UK life sciences companies will need to sell in a global market. That requires a layered business structure that works across national boundaries, according to Mike Anstey, partner at Cambridge Innovation Capital. One successful model is for a UK-founded business to maintain core aspects of R&D locally, and then establish a meaningful presence in the US or other markets, in order to have a global view. “Bicycle Therapeutics is an example that plays to both UK and US ecosystems,” says Mike. “It is headquartered in the UK but would be limited if the entire business stayed here in Cambridge. What we see as a success is not about ‘lift or shift’, where you go from a UK company to a US company,’” he concludes. “It’s about an expansion of the UK capability.” So while some companies will opt for a London listing, some will be built for acquisition from the start, and others will choose to land in the US while maintaining a UK footprint—that mix is essential to maintaining a vibrant life sciences ecosystem. Guest contributor Alexandra Black. The author would like to thank Mike Anstey, Barbara Domayne-Hayman, Alan Hirzel, Eliot Forster, Hakan Goker, Eddy Littler, Daniel Mahony, Robert Tansley, Will Walker-Arnott, Tom Weaver 28 | One Nucleus Annual Review & Directory 2021/2022

PORTWAY RENDERING

Locate Your Business at the Centre of Science

GRANTA PARK

The Portway Building offers up to 98,400 square feet of quality office and fully fitted, flexible state-of-the-art laboratory accommodation. Granta Park is located in the heart of the Cambridge science cluster and offers 120 acres of truly inspirational surroundings, creating a perfect environment for a work-life balance. Available Q4 2021.

www.theportwaybuilding.co.uk

www.onenucleus.com | 29

COVID-19: A Catalyst, not Cause, for Growth in Life Sciences COVID-19 has put the life sciences industry under the global spotlight – or perhaps more fittingly, microscope – in a way few could ever imagined before. Companies such as AstraZeneca and Pfizer are now household names thanks to their leading role in vaccine development and manufacturing. Going forward, successful research outcomes will continue to raise both the profile of the life sciences industry as well as the amount of capital looking to be invested to drive lifesaving therapies, diagnostics and vaccines. Yet, even before coronavirus had entered everyday speech, the life science industry was benefiting from increased attention and investment. This can be seen in the numbers: global pharma R&D spending has more than tripled since 2000, reaching an estimated $200B in 2020. Plus, last year we saw record capital inflows into life sciences and 74 IPOs, well above historical average. This included eleven BioMed tenants, such as Poseida Therapeutics, Generation Bio, and Silverback Therapeutics, totaling $3.3bn raised. The pandemic has shown that while some industries can operate successfully while working remotely, essential lab work and drug discovery cannot be done from home. COVID-19 has tested every asset class and in times of crisis, the life science industry has proven to be resilient. We expect to see growing investment into life sciences companies – and also the real estate that supports them – that stretches beyond the pandemic. The pandemic has since proven that many industries can operate successfully with remote working. However, lab work and drug discovery cannot be done from home, which is why 100% of our assets have remained open, allowing researchers to conduct essential work even while other workplaces were shut. Further, life science buildings are highly differentiated from traditional offices. A purposebuilt life science building requires much more robust infrastructure and floor-to-ceiling height while also providing redundant power, specialized HVAC equipment, and greater loading capacity. The increased pace of innovation – and higher levels of funding – mean life sciences occupiers’ real estate needs can change quickly, so flexibility is key. On one level, flexibility means creating buildings that can easily be repurposed for future tenants’ needs. On another, it means being able to offer occupiers the space they need as they scale up - or down - as we can across our 13m sq. ft. operational portfolio that is 100% concentrated in core innovation markets in the US and UK. Our vertically integrated platform, supported by 230 experienced professionals covering all aspects from development through to leasing and operations, means our tenant partners can focus on the science while we handle the real estate. In the post-pandemic era, we expect to see a lot more of both. www.biomedrealty.com 30 | One Nucleus Annual Review & Directory 2021/2022

A Year in the Life of a Pandemic Each new edition of the One Nucleus Annual Review is an opportunity to reflect on the past 12 months, our members and region’s success put in perspective of the wider context. And what a context it was in 2020 -21. A mix of operational challenges for companies and unprecedent global spotlights for our industry resulted in another record year for investment (£2.8bn in total for UK biotech in 2020) and an interesting dynamic for growing companies. Here we highlight some of these trends considering recent major regional deals. Acknowledgement of Scientific Excellence With good cash flow levels and an ongoing appetite for innovation we have seen great M&A activity in the region. The biggest headlines focused on the Kymab acquisition by Sanofi for an upfront payment of $1.1bn and GW Pharmaceuticals by Jazz Pharmaceuticals for $7.2bn on Nasdaq in early 2021. These major deals are increasing the excitement for the potential of medicines development and regional R&D investment they represent; but they are also rightly raising concerns around the loss of national – and regional – ownership of two major technology gems. This is developed on p.26 and maintaining a half full version of the glass, it is a fantastic acknowledgment of the region’s capacity to innovate, that was also exemplified by Kandy’s acquisition by Bayer for $425M upfront or Nanna Therapeutics by Astellas for £12M upfront in 2020. Another aspect of this appreciation is the capacity that some local companies demonstrated to access public market investment for growth to pursue development programmes. This included the F-star IPO (reverse merger on Nov 20), Freeline Therapeutics (IPO on Aug 20) and more recently Achilles Therapeutics (March 21). A more educated generalist investor population and public markets that had to rely on fewer industries economically contributing, has led to a boom in – primarily Nasdaq – biotech IPOs in 2020. This revives the debate on the differences between how the capital markets on both sides of the Atlantic approach biotech but in this context it is a fantastic opportunity for innovative companies to pursue clinical developments in the best financial conditions. Another great example of the capacity to raise investment on Nasdaq is Abcam that closed its US IPO at $180M to reinforce their position as discovery partners building on their full cycle antibody expertise. Trust in the capacity to grow One of the main highlights of the last 12 months is the size and number of followon rounds (series B+). These deals seem to be more accessible and larger, providing companies with better scaling prospects. It is a national trend – the UK hit a record £1.39bn of private capital investment in biotech in 2020 – but the region clearly stands out with over £700M of private capital raised in the period March 20 – March 21 mainly for series B+, some of them reaching record amounts.

www.onenucleus.com | 31

Below we highlight some of these deals. Evonetix $30M Series B March 2020 Led by new investor Foresite Capital. Existing investors, Draper Esprit, DCVC (Data Collective), the Morningside group, Providence Investment Company, Cambridge Consultants Ltd, Rising Tide Fund, and Civilization Ventures, also all participated in the round. Bit bio $41.5M Series A June 2020 Rick Klausner, Bob Nelsen, and Jim Tananbaum, Foresite Capital, Blueyard Capital and Arch Venture Partners NodThera $55M Series B June 2020 Led by Novo Holdings and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital Mission Therapeutics Pfizer Venture

$15M Series C extension

July 2020

ReViral $44M Series C August 2020 Led by CR-CP Life Science Fund. Additional investors include Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors. Revolo Therapeutics (Immune Regulation)

$53.4M Series B

September 2020

Led by Morningside Ventures, including existing 24Haymarket and additional capital raised to Metellus AG CellCentric Led by existing investor Morningside Venture Congenica

$33M

October 2020

$50M Series C

November 2020

Co-led by Tencent and Legal & General with new investors Xeraya, Puhua Capital and IDO Investments. Existing investors Parkwalk, Cambridge Innovation Capital and Downing also participated. Inivata

$35M second close of Series C

February 2021

Led by Soleus Capital, joined by new investors including Janus Henderson Investors and Farallon Capital alongside existing investor IP Group. This latest funding takes the total raised in the Series C to $60M following the $25M invested by NeoGenomics. Phoremost

$46M Series B

March 2021

Led by BGF and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.

32 | One Nucleus Annual Review & Directory 2021/2022

We can see a healthy mix of technology providers as well as drug development companies reflecting on the regional excellence in areas as varied and complementary as synthetic biology, stem cell technologies, genomics, therapeutic antibodies and/or innovative small molecules. The confidence shown by existing as well as new investors in these companies to grow is a very positive sign for their development into the next phases, growing hopes for the region’s strengths in these areas. Risk taking If we have seen record breaking investment in the intermediary and later stages, concerns remain around the most risk-taking early phase investments. First-time fundraising that was already on a fragile slope seems to have been the most affected in 2020. It saw a significant drop in equity-backed start-ups reflecting the temporary uncertainty from investors but also the increased difficulties for those needing to build a network to do it from home. Despite the lower figures, even in tech where first time rounds were 15% down compared to 2019, there are reasons to be positive, especially in our region. Local companies did well in raising their seed and Series A funding. Examples again span across the drug discovery and technology space including the likes of Mursla, Spirea, Pharmenable (£1.8M), Qkine (£1.5M), Microfluidix (£1.4M) ensuring a strong pipeline. No immediate deal does not mean there is no activity in the early-stage start-up scene. Our region is lucky to have solid initiatives supporting this scene and catering for different stages and business models. With accelerate@Barbraham hosting their third cohort, Illumina accelerator announcing a solid second cohort of European companies in Cambridge and StartCodon securing a £15M fund to accelerate their companies’ development, there is a strong support for these companies currently in stealth mode that will emerge when risk aversion fades away. Finally, as de-risking early-stage investment is not something new from the pandemic, we are seeing new initiatives worth mentioning than may have been accelerated by the context of the pandemic. The creation and $250M fundraising of Centessa being one of them. Centessa brings together 10 companies from Medicxi’s portfolio with 15 high conviction programs led by experienced teams. The idea being to combine the innovative capacity and agile programme management of biotechs with the development powerhouse and expertise of pharmas. This model is unique worldwide, and it is not a surprise that 3 out of the 10 companies are Cambridge, UK based. In conclusion, the ‘year in the pandemic’ has been challenging yet full of promise for those involved in life sciences. Companies in our region keep growing as we can see from the deal and fundraising figures but also from more intangible signs like recruitment increasing and lab space more than ever in demand. We are looking forward to even better data for next year’s review and importantly seeing the great benefits for patients and society our biotech ecosystem is bringing. Foreword by Aline Charpentier, One Nucleus

www.onenucleus.com | 33

Laboratory Services

If you’re relocating your laboratory, Restore Harrow Green are the experts you can trust to handle every aspect of your project. Our advanced knowledge of laboratory operations means we are able to handle: Samples, and chemicals, including dangerous & hazardous goods All types & sizes of moves, specialising in complicated projects Instruments and all types of equipment Cold chain materials IT, data and archives Clean Rooms Office, write up, and break out areas Glasg

We provide: A high Level of Service & Technical ability

Manc

heste r

Leed

A dedicated Lab Project Manager An in-house DGSA

Birm

ingha

Bristo

We have branches in every major UK city and can undertake any size lab move. We also store and distribute all types of equipment. In addition, our new, lab dedicated facility in Cambridge, was purpose built to support the area’s research parks and wider scientific community.

ridge

Lond

We guarantee: Your peace of mind! www.harrowgreen.com RHG Laboratory Services

@HarrowGreen

34 | One Nucleus Annual Review & Directory 2021/2022

Camb

labprojects@restore-harrowgreen.com 0345 603 8774

PrecisionLife drives precision medicine for COVID-19 and beyond Simon Beaulah, SVP Healthcare, PrecisionLife The drastic variability in response to COVID-19 infection has raised awareness of the importance of each person’s genetics and comorbidities. Precision medicine approaches have been successful in oncology and rare disease and there is a strong interest in applying these techniques to COVID-19 and looking further ahead into chronic diseases. Large scale genetic COVID-19 studies by 23andMe and the COVID-19 hgi group have struggled to find significant insights with only 11 and 15 loci identified as associated with severe outcomes and are not sufficient to explain the variation in symptoms and disease severity. Why is it so challenging to unpick the biological drivers of complex infections like COVID-19 and chronic diseases like Alzheimer’s, diabetes and CVD? The answer lies in the combinatorial effects of many relatively common SNPs acting together to have a non-linear effect on disease instead of a few genetic points of failure, such as those found in oncology and rare disease. Our platform identifies these combinatorial effects of genomic, clinical and epidemiological factors to unpick the underlying biological factors associated with specific disease sub-groups. PrecisionLife analyzed mild and severe COVID-19 patients in UK Biobank using our proprietary mathematical platform and identified 168 SNPs associated with severe disease, mapping to 88 risk related genes and 23 druggable targets1. We see huge potential and exciting results in using our PrecisionLife platform to develop insights into the non-linear effects of genetic and metabolic interactions that underly chronic diseases such as asthma, diabetes and cardiovascular disorders. The patient stratification and disease insights we generate from large scale clinical and ‘omics data sets are used to pursue three key applications across life sciences and healthcare: novel drug programs, stratification biomarkers, and clinical risk scores. We have R&D collaborations in progress in non-T2 asthma, schizophrenia and ALS to deliver novel targets and associated data packages to our pharmaceutical and diagnostic partners. Our exciting new programs in Alzheimer’s, COPD, endometriosis and type-II diabetes are revealing disease subpopulations that are driven by specific biological processes. Our Alzheimer’s work for example has found six patients subgroups with distinctly different mechanistic drivers of the disease, perhaps showing why there have been so many issues with clinical trial efficacy. We see our ability to map biological drivers of disease to specific patient subgroups as a major competitive advantage and key to reducing the 60% of phase three trials that fail because of efficacy issues. PrecisionLife has also partnered with leading AI drug discovery companies to provide small molecular development and biological assay capabilities. This portfolio approach is allowing us to develop multiple innovative targets addressing unmet medical needs to the in vitro validation stage in a much shorter time frame than conventional approaches, reducing the time from the typical 3–5 years to months. With many areas of unmet medical need to address, we are constantly searching for new disease data sets and collaborations to apply our platform to. To find out more or to explore partnership opportunities please visit www.precisionlife.com

COVID-19 disease architecture diagram demonstrating patient subpopulations generated by the PrecisionLife platform. Each circle represents a diseaseassociated SNP genotype, edges represent co-association in patients, and each color a distinct community of SNPs.

www.onenucleus.com | 35

catalent expands into plasmid dna manufacturing

DEVELOPING CELL & GENE THERAPIES IS SCIENCE. ORCHESTRATING RAPID SCALE-UP IS ART. Successful cell & gene therapies are built on innovative cellular science, viral technologies and the art of orchestrating fast and scalable manufacturing processes. Catalent’s proven expertise across multiple cell and viral modalities, development technologies and accelerated scale-up to commercial supply, help turn your science into approved treatments.

autologous | allogeneic | viral vectors | advanced vaccines | oncolytic viruses

WHERE SCIENCE MEETS ART.™ 1 888Nucleus SOLUTION (765-8846) 00800 8855 6178 biologics.catalent.com/cellandgene 36 us| + One Annual ReviewEUR & Directory 2021/2022

Cell and Gene Therapy: Opportunities and Challenges Colleen Floreck, Vice President of Marketing and Strategy, Cell and Gene Therapy, Catalent Cell and gene therapies are entering the pipeline at an increasing rate, due in part to Fast Track designations accelerating agency approval timelines. These advanced therapeutics offer the hope of a cure for diseases that can otherwise potentially cause a lifetime of debilitation or early mortality. Gene Therapy Gene therapy treatments use viral vectors to deliver genetic material to patients with rare diseases, and of the viral vector types used by gene therapy innovators, adeno-associated viral (AAV) vectors have proven to be a safe platform. AAV manufacturing is challenging, and does not have years of standardised, regulatoryapproved production processes to use as a basis for commercial-scale production. Scalability challenges and non-standard expression systems, combined with high demand, has led to manufacturers having to employ innovative technologies in process optimisation, analytical development, supply chain and commercial-capacity planning to mitigate these challenges. To ensure investment, innovators must adopt a commercial manufacturing plan early, and secure scheduled manufacturing space as soon as their programme shows promise. High market demand, alongside complex manufacturing processes and limited global expertise, has led to a surge of outsourcing to contract development and manufacturing organisations (CDMOs) offering capacity and processing expertise for late-stage manufacturing. CDMOs can offer experience across multiple cell and viral types as well as treatment modalities, and with expanded offerings in raw material supply of expensive starting material such as plasmid DNA, customers can feel confident that supply chains are secure. CDMOs can also allow access to emerging technologies that can assist in improving vector yields and process efficiency. Cell Therapy Cell therapies, such as those driven by chimeric antigen receptor T cells (CAR-T), use reprogrammed immune cells to attack solid or suspension tumour cells. There are two different forms of CART-T cell therapy: autologous, where patients’ white blood cells (specifically cytotoxic T cells) are removed, isolated, purified, expanded, transfected using recombinant viral vectors, and ultimately returned to patients; and allogeneic, where cells are drawn from healthy donors and prepared for delivery to ill patients. Autologous cell therapies are patient-specific, so separate batches must be produced for each patient, limiting production standardisation across multiple patients. Scale-out

www.onenucleus.com | 37

is often complex and costly, requiring handling of multiple batches concurrently, while maintaining the need for patient-specific customisations, adding risk and the need to avoid contamination between patient batches. Allogeneic cell therapy removes bottlenecks of variable cell activity compressed preparation times. This approach has many advantages, such as offering off-the-shelf batch availability; possible standardisation of cell product from healthy donors; and potentially, multiple CAR-T cell modifications. However, there have been concerns with allogeneic cell therapy modalities around potential immunogenicity and manufacturing at scale. Catalent has adopted a “Manufacturing by Design” methodology for allogeneic cell therapy production, which creates a customised approach to each project. It includes a detailed diagnosis of the client’s process, growth optimisation techniques, and scalable development and manufacturing. Strategic partnerships with key advanced therapeutic companies, coupled with a strong commitment to invest in innovative technologies, equipment and facilities, positions Catalent as an ideal manufacturing partner for cell and gene innovators’ clinical pipelines.

38 | One Nucleus Annual Review & Directory 2021/2022

Pharmidex is a CRO providing high quality solutions in: In-silico modelling ADMET & DMPK Bioanalysis (non-GLP, GLP/GCP) Metabolite Identification Toxicology (non-GLP, GLP) Efficacy models supporting CNS, Oncology, Respiratory & Inflammation

bd@pharmidex.com www.pharmidex.com

Your employees are your most valuable asset, and training is an investment in the future of your business. Register your employees for a One Nucleus Training Course today.

www.onenucleus.com | 39

The Year That Put Laboratory Automation on the Map Jill Hronek, SLAS Director, Marketing & Communications The use of automation tools in the research laboratory has been expanding steadily for decades. But 2020 and the pandemic response truly brought automation to the forefront across the globe. For SLAS and countless life sciences researchers, automation played a vital role in accelerating research, diagnostics, testing methods and eventually vaccine development. It also became a critical tool to respond to increased throughput and overall utilization of hours available in a day, when COVID dictated the need for social distancing and other work restrictions. But automating a laboratory is a process, not a purchase. Having a solid plan, a diverse team and a clear understanding of why you want to automate is the critical first step. For instance, is there a specific opportunity that can only be achieved through automation? Are you trying to achieve efficiency or cut down on labor-intensive processes? The next important step is defining and agreeing on deliverables: stick to what you want to achieve and don’t let “shiny objects” get in the way of that intent. Defining what is NOT in your scope of automation is as important as what’s in your plan for automation. Communication and the Right Team Are Keys to Success To ensure success you need to have the right people and skill sets on the automation integration team. “Collaboration and good communication are key,” says Zoe HughesThomas, Head Medicine Design Automation at GSK. Hughes-Thomas and other experts joined SLAS and One Nucleus in a three-part webinar series: “Turn Your Lab Automation Plans into Action” in late 2020. “Automation experts, external vendors and scientific experts are obvious players...but the buy-in and involvement of your data experts, safety team, finance, facilities and representatives from other impacted workstreams...can unearth sticking points in the process, roll-out or even design, that might get missed.” Change management across the organization should not be underestimated. People who are directly or indirectly impacted by new automation will wonder how it will impact their job and may be instinctively suspicious of its value. If expectations are communicated at all steps along the way, your team can share the excitement, skill up to help make the transition easier after the install and support the opportunity it brings. Pace Yourself The best thing about automation is that you can start small and scale-up as needs and ability mesh. Maximizing your initial investment will be key. Ask yourself: Is your assay ready? Is it robust and reproducible? Do your reagents require special handling or temperature settings? Capture those needs before you look toward future goals. “There are a lot of ways to automate,” says David Fuller, CEO of Artificial Inc. “Most biotechs move through the phases from lightly automated bench work to fully automated and making those decisions as to when, how, and why are the critical piece.” 40 | One Nucleus Annual Review & Directory 2021/2022

Do you have the skill set in-house to manage the automation once you have it? How much support will you need and who provide that support – the vendor or a third-party consultant? Be considerate of the training you will need to run the new machines to ensure you maximize your investment. When is Automation NOT the Answer? You need to understand whether what you are trying to automate is an ongoing need or a one-off large-scale experiment. It might make more sense to outsource the experiment than invest in something that doesn’t serve a long-term vision. Do you need to bring all the automation in house? “No, you don’t,” says Daniel Sipes of Strateos, a robotic cloud laboratory for life sciences. Have you arrived at some mechanism where you have a repeatable element to your protocol? Once you’ve done the CostBenefit Analysis you can make the right decision as to what’s next. Data is the Future Automating processes means generating even larger volumes of data but all the automation in the world is useless unless you can analyze and make use of the data it generates. Virtual reality and augmented reality tools are maturing and offer powerful new possibilities for visualization and collaboration. Likewise, new machine learning and AI tools expand the quality and usefulness of the vast volumes of data we generate. “On the path to the lab of the future, the next step is going to be about harmonization – harmonization of data communication and the digital infrastructure our researchers are living in,” says SLAS President Hansjörg Haas, Senior Director and General Manager of Laboratory Automation at Thermo Fisher Scientific. “Bringing information together in a form that can create knowledge faster – THAT’S what will help us to transform research.” View the three-webinar series produced by One Nucleus and SLAS – Turn Your Lab Automation Plans Into Action -- available at no cost on the SLAS APPLIED online education platform or on the One Nucleus YouTube channel. •

Part 1: Setting Goals That Deliver

•

Part 2: Creating Effective Workflows, Teams and Tools

•

Part 3: Swimming in Data: How to Generate Useful Returns

For more information visit www.slas.org

www.onenucleus.com | 41

Marks & Clerk Extended Reality Post-Covid

Virtual reality (VR) first hit the news in the early 1990s but then sank without a trace. It returned with a vengeance a few years ago and quickly gained more traction than the first time round. This wasn’t just because of technological advancement from its first incarnation. Its applications had widened too. Firstly, VR as a completely simulated experience had been joined by the imposition of computer generated elements on a real environment (augmented reality or AR) and the blending of real and virtual worlds to create new environments (mixed reality or MR). Extended reality or XR is the umbrella term given to all these. Secondly, whereas what started out as a more immersive version of computer games technology was initially viewed primarily as a new form of entertainment, the second time round the full range of its potential has been recognised. XR applications are thriving in fields such as product design, education, training, diagnosis and treatment. Admittedly, there have been some barriers to market, such as security concerns, bandwidth and connectivity challenges and the cost and size of the hardware but then along came Covid-19. Whereas the pandemic has been a bane to so many sectors, it proved a shot in the arm for XR. In a world in which travel was limited and personal contact became lifethreatening, the sophistication and immersivity of XR as a tool for remote interaction has proved to be a godsend to many disciplines and industries. The life sciences and healthcare sectors are no exception. VR can be used to supply engaging education and training so that one can learn skills such as anatomy, how to interact with a patient, laboratory procedures and surgical techniques in a risk free but increasingly realistic environment. Experiments can be conducted without the results blowing up in one’s face literally even if they do so virtually or metaphorically. Product design, whether it be putting molecules together to form a novel compound or designing a ventilator for Covid-19 patients, can be carried out without need for a laboratory or involving collaborators on opposite sides of the world, whose avatars can interact face to face using a virtual meeting facility. VR has proved especially useful in diagnosing and treating psychological and neurological conditions. Once we get back to normal, the old ways of doing things will return up to a point. Some things do need doing for real and people crave changes in their environment and real personal contact but, in many respects, the XR revolution is here to stay and its progress will be buoyed by its pairing with other emerging technologies. A surgeon trained in VR can now operate remotely on a 5G network, using AR glasses to guide an AI-powered robotic surgeon. If in the long run that is safer and cheaper than the old way then the end of lockdown is unlikely to put the genie back in the bottle.

42 | One Nucleus Annual Review & Directory 2021/2022

OneNucleus150 AND SAVE

A PRODUCT OF

www.onenucleus.com | 43

AMR: Now more than ever, and still, a problem to be addressed Antonio Felici, VP Anti-Infective, Evotec

The Covid-19 worldwide pandemic unveiled extraordinary resources in the scientific and pharmaceutical community to deliver vaccines and therapeutic drug candidates after fast clinical trials and within such short timelines as never seen before. While this pandemic was sudden and the number of cases increased exponentially, the AMR crisis remains silent. Is AMR our next pandemic? Possibly, if we continue to use antibiotics to put out fires: you won’t start creating them until you are facing a fire. Innovation and collaboration are key in preparedness, together with expertise and operational excellence that Evotec brings with more than 200 people dedicated to antibacterial drug R&D. Innovative thinking and creativity to discover novel antibacterial compounds start from designing a strategy to discover novel active compounds. By changing the paradigm in phenotypic screening and developing the Vivo Mimetic Media (VMM) concept for discovering novel Gram-negative antibacterials, Evotec validated five alternative bacterial culture media that better mimic the conditions bacteria are facing during infections. These VMM conditions are affecting the physiology of growing bacteria by altering permeability (porins, efflux pumps, outer membranes) but mainly unveiling new targets and MoAs, dispensable in rich media and essential in VMM and in vivo. A cornerstone of innovation in antibacterial drug discovery is the application of machine learning to optimise chemical matter. By combining biological data, medicinal chemistry expertise and a deep learning approach, an Evotec program has allowed the prediction of antibacterial activities against 15 bacterial strains and provided de novo design of compounds, 76% of which were accurately predicted for their activity. Validation of active compounds in appropriate pharmacodynamic models is crucial, while innovative approaches are needed for tailored design and improved readouts. By using luminescent or fluorescent bacteria, infection models with higher complexity have been developed at Evotec and allowed, for instance, to evaluate the spread of infection in real time and, most importantly, measure the distribution of the active compound fluorescently labelled to the site of infection. Innovation through collaboration and partnership is a potent value-creation model. Based on a partnership between Evotec, Resolute Therapeutics and CARB-X, the TriBe new antibacterial drug class is being advanced in the preclinical pipeline with the objective to bring a candidate for treatment of cUTI, cIAI and lung infections to clinical phase I. The TriBE series have unique properties with nanomolar bacterial topoisomerase inhibitors via binding to the GyrB/ParE subunits, very broad bacterial spectrum, low potential to select for resistance, favourable PK and have demonstrated in vivo efficacy in multiple models of infection. While a consensus exists on the real and clear need for new antibacterials and approaches, the challenges are numerous and complex. Innovative thinking, creativity and novel approaches (target and technology) are undertaken at Evotec to redesign antibacterial discovery, ensure an integrated approach and foster collaboration, partnership, training and cross-interaction. For more insights into innovative approaches in AMR, watch the Genesis 2020 session ‘Innovation to fight AMR’. 44 | One Nucleus Annual Review & Directory 2021/2022

Thermo Fisher COVID-19’s silver lining: Accelerated Vaccine Development via new generation vaccine platforms Vaccine development is a lengthy process—it is expensive, attrition is high, and to get a licensed vaccine to everyone, it takes multiple candidate iterations. Vaccine development for pandemics and epidemics is risky, and due to the novel nature of viruses, certain unknown factors can derail a vaccine program. With the spread of SARS-CoV-2 intensifying, scientists, together with pharmaceutical companies, are reinventing the approach of how to bring these life-saving drugs to market faster without impacting product quality, safety, or efficacy. When it comes to vaccine development there are two approaches—or platforms— developers can utilize: traditional platforms or new generation platforms. Traditional vaccine platforms are tried and true approaches to vaccine development. They have strong and robust historical data and many of them have relatively simple formulation. Most current and licensed vaccines for human use are either virus- or protein-based vaccines. However, the limitations of traditional vaccine platforms make them less ideal for trying to develop a vaccine quickly, in response to a pandemic. Introducing new generation vaccine platforms Unlike traditional platforms, new generation vaccine platforms can go off genetic sequence information alone. DNA and RNA-based platforms only require laboratory synthesis, not culture or fermentation—there isn’t a need for a dedicated biosafety facility as there is no handling of infectious material. This speeds vaccine development exponentially. Furthermore, vaccines based of viral vectors offer a high level of protein expression, longterm stability, and can introduce a strong immunic response.

Among the emerging technologies transforming vaccine development are viral vectors, which also play a fundamental role in the race for the SARS-CoV-2 vaccine.

www.onenucleus.com | 45

Though new generation vaccine platforms are ideal during a pandemic, they have own fair share of challenges. RNA’s are sensitive and need something to preserve them. To help preserve the RNA, lipid nanoparticles are used which adds quite a bit of complexity. Furthermore, RNA-based platforms are poorly stable at room temperature, making the need for sub-zero storage and supply chain monumentally important. Additionally, DNA-based developed vaccines could require special medical devices to administer the vaccine. Despite the challenges, its more streamlined process and approach is just what developers needed to get out a COVID-19 vaccine, fast. Transforming medicines with scale, flexibility and expertise Thermo Fisher Scientific is proud to support biopharma, academia and government customers to develop and commercialize both therapeutics and vaccines to fight the COVID-19 pandemic. As the pandemic battle wages on, we also recognise that we must continue to be vigilant in delivering critical non-COVID-19 medicines, because a patient’s need for treatments for cancer, genetic diseases and other conditions doesn’t stop during a pandemic. Find out more about the services we provide. To learn more about COVID-19’s impact on vaccine development and how experts have responded, download this whitepaper. For more information visit www.corporate.thermofisher.com.

46 | One Nucleus Annual Review & Directory 2021/2022

HOW VIRAL VECTOR TECHNOLOGY IS RAPIDLY SCALING UP TO ENABLE ONE MIRACLE AFTER ANOTHER

Katie Shannon Senior Director of Engineering Viral Vector Services Cambridge, MA

MADE WITH COMMITMENT & CAPACITY

The promise of viral vectors has been pursued for over two decades. But in the last few years, this transcendent technology that’s targeting over 200 diseases has finally started to create real treatments and possible cures. This sudden momentum has put Katie and her team to the test. With major capital investments, they’ve built out Thermo Fisher’s Viral Vector capacity in just under 30 months, across three locations. Katie has had to customize these locations to the new and innovative technology, and constantly shifting demands. As she says, “we’ve literally had to move walls while we’re in the middle of building them.” But nothing stops her and her team. Not even 50 tons of boulders discovered beneath a construction site. In spite of the obstacles, she and her team build for maximum flexibility, even with the demands of the most precise science on the line. With three viral vector manufacturing sites and more on the horizon, engineers like Katie and her team are paving the way for pharma and biotech companies to bring new treatments to market, and potentially save millions of lives. Find out more at thermofisher.com/patheon

www.onenucleus.com | 47

It takes a Network… More than a membership organisation, One Nucleus is a network offering many forms of interaction and benefits. Imagine it as a social group with a nucleus of core participants who are active in managing its activities and working on maintaining connections – this would be your devoted One Nucleus team! – the other elements of the group would then interact as much or as little as they want but sharing a common goal. For the social group it could be as simple as having fun, and for a group like One Nucleus it is to leverage collective strength and intelligence to progress their business, careers and R&D. As there is no better place than the annual directory feature to reflect on this network as a whole, here is a representation of the One Nucleus network and importantly our valuable members. Introducing One Nucleus membership There are numerous reasons for becoming a One Nucleus member which could be to benefit from profiling opportunities, making new contacts, sharing and learning with peers or saving money with our purchasing scheme but there is always one common factor: the contribution to the life science value chain. This value chain ranging from public research to large corporations with all stages of companies in between is fully represented in the One Nucleus membership accounting for 27% of its total. The discovery and development backbone could not develop without the increasingly specialised support from technology providers representing another 33% of the network and ranging from the niche technical services in data, chemistry or biology to the broad spectrum CROs and CDMOs. The rest of the support is a highly specialised group of professional services helping companies operations as well as their strategic development.

48 | One Nucleus Annual Review & Directory 2021/2022

Here is a more detailed representation of One Nucleus members with examples. The breadth of expertise and span of company size is a great reflection of the wider One Nucleus community and one of the keys for the network’s success.

Understanding the regional anchorage

Even if the membership is the core group involved in the One Nucleus activities, the network is wider than that, making it stronger thanks to its geographical anchorage, the East of England. Institutions or even R&D companies may not all be members at one point in time as they may not be at a stage to benefit fully from it, yet still engage with the One Nucleus community. Our understanding of this ecosystem and flexibility in involving them regardless, engagement is what makes One Nucleus the go-to network to develop in the East of England.

www.onenucleus.com | 49

Here is an overview of the East of England life science technology coverage that we are very proud to know enough to map and to claim an engagement rate of over 80% with this vibrant R&D scene. Therapeutics Biotech in East of England

This graphic reflects the key technology expertise in the East of England region which is going from strength to strength, as described in the article on p31. In conclusion there are many ways to interact with the One Nucleus community but it always has to start by acknowledging this community: the members and the wider network. The annual review is a good place to start for that with the following A- Z list of members. We also hope it will help to reflect on these ‘big problems’ networks are supposed to help solve; generating the best biotech innovations, developing the best interventions and being the best life science cluster, while having fun doing what we do.

50 | One Nucleus Annual Review & Directory 2021/2022

www.onenucleus.com | 51

Up to 30% off Training Courses for One Nucleus Members Courses include: • • • • • • •

Introduction to Drug Discovery Biological Safety: Management and Practice (IOSH Approved) Introduction to Managing Life Science Projects Presentation Skills for Scientists Laboratory Health & Safety The Safe Use and Management of Lab Gases BioSafety Masterclass

Visit onenucleus.com/training-courses to see the list of current training course we have to offer.

Member A-Z Listing

www.onenucleus.com | 53

A-Z Listing A

Artemida Pharma Artios Pharma Limited

001 Limited

Astellas Pharma Europe Ltd

A4Pbio

Astex Pharmaceuticals Ltd

Abcam plc

AstraZeneca

Abingworth LLP

Atelerix Ltd

Actigen Limited

Aurigene Pharmaceutical Services Ltd

Adrestia Therapeutics Ltd

Autolus Limited

Advarra

Avacta Life Sciences Ltd

Advent Life Sciences LLP

Avidity IP Limited - Life Sciences Team

Agenda Life Sciences

AZoNetwork UK Ltd

Agenus UK Limited Agility Life Sciences

Aglaris

Babraham Institute Enterprise Limited

Air Liquide UK Ltd

Babraham Research Campus

Air Products PLC

Baccuico Limited

Alchemab Therapeutics Ltd

BBI Cambridge Ltd

Alkamis Pte Ltd

Beauchamp Technology

Alloy Therapeutics UK Ltd

BenevolentAI

Alpha MD Limited

BicycleTx Limited

AltemisLab Limited

Bio Transcript Partners LLP

Amphista Therapeutics Ltd

Biocair - UK

Amphora Research Systems

Biocrucible Ltd

AMS Advanced Medical Services

Biofidelity Limited

AMS Biotechnology

BioIVT

Anatomise Biostats Ltd.

BioM Biotech Cluster Development GmbH

Anthony Nolan

BioMed Realty

Antikor Biopharma

BioNJ

Apollo Scientific Limited

Bionow

Apollo Therapeutics LLP

BioPartner UK

Apple Tree Life Sciences (UK) Limited

BioPharmaLogic LLC

Appleyard Lees IP LLP

Biorelate Limited

Aqdot Ltd

BioStrata Marketing

Arecor Limited

Biosynergy (Europe) Ltd

Arise Innovation Centres

Biotechnology Innovation Organization (BIO)

54 | One Nucleus Annual Review & Directory 2021/2022

A-Z Listing bit bio Ltd

Charles River Associates - Cambridge Life Sciences

Blue Link Worldwide UK Limited

Charles Stanley & Co. Limited

BOC

Chesterford Research Park

Boehringer Ingelheim

Chiesi Limited

Boult Wade Tennant

Child Growth Foundation

Boyds

CIMYM BioSciences Ltd

Bridge Partners Ltd

Closed Loop Medicine Limited

Bristows LLP

CMS Cameron McKenna Nabarro Olswang LLP -

Broken String Biosciences Ltd

Life Sciences Team

Bruntwood SciTech

CN Bio Innovations

Business France - Healthcare/Biotech Team

Collaborative Drug Discovery

Colorifix Ltd Compugen - UK

Cambridge Design Partnership LLP

ConcR

Cambridge Employment Law LLP

Congenica Ltd

Cambridge Enterprise Limited

Creative Places LLP

Cambridge Epigenetix Limited

Crescendo Biologics

Cambridge Innovation Capital (CIC)

Curileum Discovery Ltd

Cambridge Network Limited

CW (Cambridge Wireless Ltd)

Cambridge Pharma Limited

CY Partners Recruitment Limited

Cambridge Rare Disease Network

Cytocell Limited

Cambridge Relocations Cambridge Research Biochemicals Cambridgeshire Chambers of Commerce

Camlab Ltd

D Young & Co LLP

CAM-SCI

Daiichi Sankyo Co Ltd

Canadian High Commission

Deep Science Ventures

Cancer Research UK (CRUK)

Deliver Plus Limited

Capella Bioscience Limited

Deloitte

Catalent Pharma Solutions

Demuris Ltd

Centre for Process Innovation (CPI)

Diosynvax Ltd (DIOSVax)

Cerevance Ltd

Discovery Park Limited

Charles Consultants (Life Sciences) Ltd

Discuva Ltd

Charles River

DLRC Ltd www.onenucleus.com | 55

A-Z Listing D Domainex Ltd

Freeline Therapeutics Limited

Dr Clare Sansom Freelance Science Writer

F-star Therapeutics Limited

Dr. Reddy’s Laboratories (EU) Ltd

Fusion Antibodies PLC

Eagle Genomics Ltd

Gallagher Life Sciences Practice (UK)

Earlham Institute

GENEWIZ UK Ltd

Eastern AHSN

George James Ltd

EBD Group

Giggabox Ltd

EIP

Government of Québec

Eleven Therapeutics (UK) Limited

Greenleaf Processing Ltd

Eli Lilly

Grovelands Resourcing Limited

Elixa MediScience Ltd Embassy of Switzerland

Emberion Limited

Haier Biomedical UK Limited

EMBL-EBI

Harlow Council

Empyrean Therapeutics Ltd

Harts Business Solutions

Enedra Therapeutics Limited

HC Pharma Consultancy Limited

Enplas (Europe) Limited

Health and Safety Works Ltd

Epidarex Capital

Healx Ltd

ERA Consulting (UK) Ltd

Hide Biotech Limited

Ernst & Young LLP (EY)

Highbury Regulatory Science Limited

Essen BioScience Ltd

Higher Steaks Ltd

Eurofins CerepPanlabs

Histocyte Laboratories Ltd

Eurofins Selcia Limited

Horizon Discovery Ltd

Evonetix

Hoxton Farms Limited

Evotec UK Ltd

HungaroTrial CRO - UK

ExecMind International Executive Search

Hyper Recruitment Solutions (HRS)

Findacure

Illumina Cambridge Ltd

Fish & Richardson P.C

Immodulon Therapeutics

Fisher Scientific UK

ImmuPharma

56 | One Nucleus Annual Review & Directory 2021/2022

A-Z Listing

Independent - Carlos Pittol

Labcorp Early Development Laboratories Ltd Alcon-

Independent - Clive Stanway

bury

Independent - Martino Picardo

Latham & Watkins

Independent - Miranda Weston-Smith

Leaf Expression Systems

Infex Therapeutics Limited

LEX Diagnostics Limited

Infinity BiologiX Limited

LifeArc

Inivata Limited

Lifesci Search Limited

Innomech Ltd

LifeSciences British Columbia

Innovate UK

Link China Pharma Solutions

Instinctif Partners (Life Sciences)

Link-J

Integrated Resources Ltd

Locki Therapeutics Limited

IONTAS Ltd

London BioScience Innovation Centre (LBIC)

iosBio Ltd

London Stansted Cambridge Consortium (LSCC)

IP Pragmatics Limited

Lonza Biologics Plc

Isogenica Ltd

LoQus23 Therapeutics Limited

Isomerase Therapeutics Ltd

Luna Therapeutics Ltd

J J A Kemp LLP Johnson Matthey PLC (Cambridge)

LUNAC Therapeutics Limited

M Macomics Limited

Mandeville Technology Limited Marks & Clerk

Kantify

Mathys & Squire LLP

Kao Data

Maxion Therapeutics Limited

Kathryn Simpson Consulting Limited

MedCity

Kelyon

Merck KGaA

Kenton Black Scientific Ltd

Mercury Bioscience Consultants Ltd

King’s College London (KCL)

Mestag Therapeutics Limited

KISS Communications

MetalloBio Limited

KPMG LLP (Life Sciences)

Metrion Biosciences Mewburn Ellis LLP Mi3 Limited

www.onenucleus.com | 57

A-Z Listing M

Microbiotica

o2h Ltd

MicrosensDx Ltd

Oak Zone Biotech UK Limited

Mills & Reeve LLP

Ocean Bio Limited

MIP Diagnostics Ltd

Odgers Berndtson

Mission Therapeutics Limited

Olexacon Limited

Mogrify Limited

OMass Therapeutics

Monument Therapeutics Limited

OncoLytika Ltd

MSD

Onyva the Agency

MultiplAI Health

Oppilotech Ltd

Murray International Partners Ltd

Optimum Strategic Communications

Mursla Limited

Origin Sciences Limited

MyData-T LTD

Osborne Clarke

Oxford Nanopore Technologies Ltd Oyster Venture Partners

Nanna Therapeutics Ltd National Physical Laboratory - NPL Nationwide Laboratories Neobe Therapeutics Limited

NeoGenomics Laboratories, Inc

Parkinson’s Concierge

NeRRe Therapeutics Limited

Partners& - Life Science Insurance

New England Biolabs (UK) Ltd

PCI Pharma Services

New Path Molecular Research Limited

Penningtons Manches Cooper LLP

Newcastle BioSphere

PeproTech EC Ltd

Newcells Biotech Ltd

Pharma International

Nexcelom BioScience Ltd

PharmaGuide Ltd

Nexus Intelligent Engineering

PharmaLex UK

Norwich Research Park

PharmaMedic Consultancy Limited

Novogene (UK) Company Ltd

Pharmaron

Nuclera Nucleics Ltd

PharmaVentures Ltd

Nuntius Therapeutics

PharmEnable Limited Phico Therapeutics Ltd PhoreMost Ltd Photography for Healthcare & Biotech

58 | One Nucleus Annual Review & Directory 2021/2022

A-Z Listing S PiR International

Sagittarius IP

PPMLD Ltd

Scale DX Ltd

Precision BioSearch Limited

Sciad Communications Ltd

Precision for Medicine - UK group

Sense Biodetection Ltd

Precisionlife Ltd

Shionogi B.V.

Principle Laboratories

Simcere UK Limited

ProductLife Ltd

SIP Cambridge

ProPharma Partners Limited

Sky Bio Ltd

Protogenia Consulting Ltd

Somaserve Ltd

Sookio Limited Sosei Heptares - Cambridge

QMS Consultancy Ltd

St John’s Innovation Centre Ltd

QRC Consultants Ltd

STARLAB (UK) Ltd

Quadram Institute Bioscience

Start Codon Ltd

Quality Care Cleaning Limited

STEMCELL Technologies UK Ltd

Queen Mary BioEnterprises Ltd

Stevenage Bioscience Catalyst

Queen Mary Innovation Ltd

Storm Therapeutics Ltd

Queen Mary University of London

Stratosvir Limited

(Business Development)

Sue Rees Associates

Quotient Sciences Ltd

Superdielectrics Ltd

Swift Molecular Diagnostics Limited Sygnature Discovery Ltd

Rare Biotech Ltd Reading Scientific Services Ltd (RSSL)

Reddie & Grose LLP

Talisman Therapeutics Ltd

Release Life Sciences and Diagnostics Ltd (RLS)

Taylor Vinters

Restore Harrow Green

Taylor Wessing

Richmond Pharmacology Ltd

Taylors Hill Consulting

Richmond Research Institute

The Brain Tumour Charity

RiverRhee Consulting

The Cambridge Crystallographic Data Centre

Roslin Cell Therapies Limited

(CCDC) The Communications Strategy Group Inc. The Institute of Cancer Research The Royal Veterinary College (RVC) www.onenucleus.com | 59

A-Z Listing T

Theradex (Europe) Ltd

Waracle - Digital Health

Thermo Fisher Scientific

We are Pioneer Group

tranScrip

Wellcome Genome Campus

TranSINE Therapeutics

Wellcome Sanger Institute

Trio Medicines Ltd

Withers & Rogers LLP

TTP plc

Wren HealthCare Limited

Tuspark Cambridge

Wren Therapeutics Limited

U UK Health Security Agency UKSPA University College London - SysMIC University College London (UCL) University of Cambridge University of East Anglia (UEA) University of Essex - Research and Enterprise Office University of Leicester- Enterprise & Business Development Office University of Nottingham - Corporate Partnerships

V ValiRx Plc Vector Laboratories Ltd Venner Shipley LLP Vernalis Ltd VirdisGroup Ltd Vitrolife Voisin Consulting Life Sciences, UK Ltd

60 | One Nucleus Annual Review & Directory 2021/2022

WuXi AppTec UK Ltd

Find Out More • Membership

• Purchasing Scheme

• Training Courses

• Member to Member Discounts

• One Nucleus Events

• Sector Data

• Industry Events

• Member Job Vacancies

• Facilities Management

• Member News

• Sponsorship Opportunities

• One Nucleus Blog

Did you know? If your employer is a One Nucleus Member, that means YOU’RE a Member too! How can the One Nucleus Membership benefit you? As a Member you can... • • • • •

Attend events for free or at a discounted rate Save money on third party events and services Post company news, jobs and events on our website Develop yourself via Training courses Write a guest blog for publication

Email info@onenucleus.com for more information.

www.onenucleus.com | 61

One Nucleus Limited 1012 Riverside, Babraham Research Campus, Cambridge CB22 3AT United Kingdom +44 (0) 1223 896 450 onenucleus.com

One Nucleus Limited (formerly ERBI Limited) Registered Office: 1012 Riverside, Babraham Research Campus, Cambridge CB22 3AT Registered in England & Wales No. 3990977